Advanced Enzyme Technologies (ADVENZYMES) Fundamentals 2026 — P/E 20.8x, Revenue Analysis | SniperIQ
Advanced Enzyme Technologies (ADVENZYMES) is a India-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ₹3,505 Crore, trading at ₹313.05 on the NSE. This SniperIQ fundamentals page covers Advanced Enzyme Technologies's valuation (P/E 20.8x, P/B 2.1x), profitability (net margin 22.6%), revenue (₹746 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Advanced Enzyme Technologies's market cap?
Advanced Enzyme Technologies (ADVENZYMES) has a market capitalization of approximately ₹3,505 Crore, trading at ₹313.05 on the NSE. Market cap moves with the live share price.
What is Advanced Enzyme Technologies's P/E ratio?
Advanced Enzyme Technologies's trailing twelve-month P/E ratio is 20.8x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Advanced Enzyme Technologies?
Advanced Enzyme Technologies runs a net profit margin of 22.6%, a gross margin of 60.2%, and an operating margin of 25.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Advanced Enzyme Technologies generate?
Advanced Enzyme Technologies reported revenue of ₹746 Crore for fiscal year 2026, with net income of ₹169 Crore and earnings per share (EPS) of 15.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Advanced Enzyme Technologies pay a dividend?
Advanced Enzyme Technologies offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Advanced Enzyme Technologies financially healthy?
Advanced Enzyme Technologies carries a debt-to-equity ratio of 0.02x and a current ratio of 9.78x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Advanced Enzyme Technologies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Advanced Enzyme Technologies (ADVENZYMES) the key facts are: market cap ₹3,505 Crore, P/E 20.8x, revenue ₹746 Crore, 52-week range 251.95-419. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Advanced Enzyme Technologies's full fundamentals live
Get Advanced Enzyme Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.